Ople, Eric
Amplyx Pharmaceuticals (United States)
2 papers on CoChat
Most cited papers
- Verified
Clinical Efficacy and Safety of a Novel Antifungal, Fosmanogepix, in Patients with Candidemia Caused by Candida auris : Results from a Phase 2 Trial
Vazquez, J. A., Pappas, P. G., Boffard, K., Paruk, F., Bien, P. A., Tawadrous, M., Ople, E., Wedel, P., Oborska, I., & Hodges, M. R. (2023) · Antimicrobial Agents and Chemotherapy
Antifungal resistance and susceptibilityFungal Infections and Studies
Cited by 92
- Verified
Safety and Pharmacokinetics of Intravenous and Oral Fosmanogepix, a First-in-Class Antifungal Agent, in Healthy Volunteers
Hodges, M. R., Ople, E., Wedel, P., Shaw, K. J., Jakate, A., Kramer, W. G., Marle, S. V., van Hoogdalem, E.-J., & Tawadrous, M. (2023) · Antimicrobial Agents and Chemotherapy
Antifungal resistance and susceptibilityFungal Infections and Studies
Cited by 52
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free